Sakata Y, Aoki N
J Clin Invest. 1982 Mar;69(3):536-42. doi: 10.1172/jci110479.
When blood is clotted, alpha(2)-plasmin inhibitor (alpha(2)PI) is cross-linked to fibrin by activated fibrin-stabilizing factor (activated coagulation Factor XIII, plasma transglutaminase). The amount of cross-linked alpha(2)-PI is proportional to the amount of alpha(2)PI present at the time of clotting. Plasma from a patient with congenital deficiency of alpha(2)PI was supplemented with various amounts of purified alpha(2)PI. Clots were prepared from these plasmas and were suspended in plasma containing a normal concentration of alpha(2)PI, and spontaneous clot lysis was observed. When the clot was formed in the presence of calcium ions and thereby allowing cross-linking to occur, the rate and extent of fibrinolysis were found to be inversely proportional to the concentrations of alpha(2)PI present in the clot at the time of clotting. When the clot was formed in the absence of calcium ions so that no cross-linking occurred, the clot underwent fibrinolysis at similar rates, regardless of the concentrations of alpha(2)PI in the clot. When the clot formed in the presence of calcium ions was squeezed and washed to remove unbound proteins before being suspended in plasma, the extent of fibrinolysis was also inversely proportional to the amount of alpha(2)PI cross-linked to fibrin. Similar results were obtained when the clot was suspended in buffered saline instead of plasma. These observations suggest that spontaneous fibrinolysis is mainly carried out by plasminogen/plasminogen activator bound to fibrin, and this fibrinolysis caused by fibrin-associated activation of plasminogen was mainly inhibited by alpha(2)PI cross-linked to fibrin. To further support this concept, alpha(2)PI treated with activated fibrin-stabilizing factor and that had lost most of its cross-linking capacity was used in similar experiments. This modified alpha(2)PI had the same inhibitory activity on plasmin as the native inhibitor, but gave significantly less inhibition of fibrinolysis in every experiment, particularly when the clot was compacted by platelet-mediated clot retraction or by squeezing. Thus, it was concluded that alpha(2)PI cross-linked to fibrin plays a significant role in inhibition of physiologically occurring fibrinolysis. It is further suggested that the absence of cross-linked alpha(2)PI contributes to accelerated fibrinolysis and hemorrhagic tendency in patients with congenital deficiency of fibrin-stabilizing factor.
血液凝固时,α(2)-纤溶酶抑制剂(α(2)PI)通过活化的纤维蛋白稳定因子(活化的凝血因子 XIII,血浆转谷氨酰胺酶)与纤维蛋白交联。交联的α(2)-PI的量与凝血时存在的α(2)PI的量成正比。给先天性α(2)PI缺乏患者的血浆补充不同量的纯化α(2)PI。用这些血浆制备凝块,并将其悬浮在含有正常浓度α(2)PI的血浆中,观察自发凝块溶解情况。当在钙离子存在下形成凝块从而允许交联发生时,发现纤维蛋白溶解的速率和程度与凝血时凝块中存在的α(2)PI的浓度成反比。当在没有钙离子的情况下形成凝块以致不发生交联时,无论凝块中α(2)PI的浓度如何,凝块都以相似的速率发生纤维蛋白溶解。当在钙离子存在下形成的凝块在悬浮于血浆之前被挤压和洗涤以去除未结合的蛋白质时,纤维蛋白溶解的程度也与交联到纤维蛋白上的α(2)PI的量成反比。当凝块悬浮在缓冲盐溶液而不是血浆中时,也得到了类似的结果。这些观察结果表明,自发纤维蛋白溶解主要由结合到纤维蛋白上的纤溶酶原/纤溶酶原激活剂进行,并且由纤维蛋白相关的纤溶酶原激活引起的这种纤维蛋白溶解主要被交联到纤维蛋白上的α(2)PI抑制。为了进一步支持这一概念,在类似实验中使用了用活化的纤维蛋白稳定因子处理并失去大部分交联能力的α(2)PI。这种修饰的α(2)PI对纤溶酶具有与天然抑制剂相同的抑制活性,但在每个实验中对纤维蛋白溶解的抑制作用明显较小,特别是当凝块通过血小板介导的凝块回缩或挤压而压实的时候。因此,得出结论,交联到纤维蛋白上的α(2)PI在抑制生理性纤维蛋白溶解中起重要作用。进一步表明,先天性纤维蛋白稳定因子缺乏患者中交联的α(2)PI的缺失导致纤维蛋白溶解加速和出血倾向。